The biennial Access to Medicine Index analyzes the top 20 research-based pharmaceutical companies on how they make medicines, vaccines and diagnostics more accessible in low- and middle-income countries.
This year, Glaxosmithkline retains its top ranking, which it has held ever since the index was launched in 2008. GSK is followed by Johnson & Johnson in the 2 spot, then Novartis, Merck KGaA, Merck & Co, and Sanofi in that order.
The Access to Medicine Index uses a weighted analytical framework to consistently capture and compare data from the top 20 research-based pharmaceutical companies across a set of countries, diseases, and product types. The index is funded by the Bill & Melinda Gates Foundation and the UK and Dutch governments.
See the full 2016 Index